Circulating HBsAg/IgM complexes in acute and chronic hepatitis B.

Area of Science:

• Hepatology
• Immunology
• Virology

Background:

• Hepatitis B virus surface antigen (HBsAg)/IgM immune complexes have been recently identified in the serum of HBsAg carriers.
• A solid-phase radioimmunoassay (RIA) has been developed for detecting HBsAg/IgM complexes.

Purpose of the Study:

• To investigate the diagnostic and prognostic value of HBsAg/IgM immune complexes in patients with acute and chronic hepatitis B.
• To assess the correlation of HBsAg/IgM complexes with disease progression, seroconversion, and carrier status.

Main Methods:

• Radioimmunoassay (RIA) was used to detect HBsAg/IgM complexes in serial serum samples.
• The study included 15 patients with acute viral hepatitis type B and 52 HBsAg chronic carriers.
• Analysis included correlation with hepatitis B e antigen (HBeAg) and antibody (anti-HBe) status.

Main Results:

• In acute hepatitis B, HBsAg/IgM complexes typically disappeared within 4 weeks, preceding HBsAg negativity and often coinciding with "e" to "anti-e" seroconversion.
• HBsAg/IgM complexes were detected in 48% of chronic carriers, 69% of chronic persistent hepatitis (CPH) patients, and 20% of healthy carriers.
• Complexes were found in 93% of HBeAg-positive chronic carriers and in anti-HBe positive patients, but never in e/anti-e negative patients.

Conclusions:

• HBsAg/IgM immune complexes serve as important prognostic indicators in acute hepatitis B.
• The presence of HBsAg/IgM complexes is significantly associated with different stages and forms of chronic hepatitis B.
• These complexes hold significant diagnostic value for both acute and chronic hepatitis B infections.